Cingulate INC S-1 registration statements

Cingulate Inc. has entered into a new $25 million committed equity financing agreement with Lincoln Park Capital Fund, LLC to fund its biopharmaceutical pipeline, including the anticipated NDA submission for its lead ADHD candidate, CTx-1301.

Cingulate Inc. has entered into a new $25 million committed equity financing agreement with Lincoln Park Capital Fund, LLC, while progressing its lead ADHD drug candidate, CTx-1301, towards an anticipated NDA submission by early August 2025.

Cingulate Inc. has filed an amendment to its Form S-1 registration statement to register an additional 1,500,000 shares for resale by Lincoln Park Capital, potentially raising up to $4.7 million.

Cingulate Inc. filed an amendment to its registration statement to correct a typographical error in the auditor consent filed as an exhibit.

Cingulate Inc. has filed a registration statement for the resale of up to 1,500,000 shares of its common stock by Lincoln Park Capital Fund, LLC.

Cingulate Inc. has filed a registration statement for the resale of up to 1,000,000 shares of its common stock by Lincoln Park Capital Fund, LLC, as part of a previously established purchase agreement.

Cingulate Inc. has filed a registration statement for the resale of up to 2,000,000 shares of its common stock by Lincoln Park Capital Fund, LLC.

Cingulate Inc. is offering shares of common stock along with Series A and Series B warrants, and pre-funded warrants, aiming to raise capital for research, development, and general corporate purposes.

Cingulate Inc. plans to offer shares of common stock, Series A warrants, Series B warrants, and pre-funded warrants in a public offering.